London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Perfect opportunity to invest in a good pharma business. Double digit gains expected in FY22, debt planned to be reduced to 2x by FY23 and bidders are circling. Whichever way you look at it, sp is hugely undervalued!!
Yes that’s how I saw it too….future is bright
It is certainly a jam tomorrow and the day after update….which may be intended to invite offers.
However I am getting more pessimistic about the prospects for Proleukin…..although it will probably cover its cost in the medium term it is not the great opportunity we were sold…..and competitors will soon be eating into its market…..hopefully it is lesson learned not to buy a product as its appeal wanes to its owner…..better to take a share of revenue and distribute rare disease medications outside US and China main markets… capital lite more predictable and a strength that can be grown.
Undervalued yes…..but PE will not be able to pay too much because the co is already loaded with debt…a good 2021/22 could see it rise back to 800, with further progress in 23. However there have been a number of mishaps in the last few years which is why it is around half the price it was when it acquired quantum pharma.
That might make sense if there had been no global pandemic…..but there has.
It’s far from the only business to have had Covid impact yet you seem to be completely ignoring that!
Can obviously see where you're coming from on your views on proleukin and it's clearly not doing what was expected of it which is why it's being called out, but what you're missing is the end goal which is the novel TIL therapies that the likes of Iovance are in the process of developing and which we've been told require the use of proleukin alongside it. Most scientific commentators are clear that TIL is the way forward and it will be a game changer in oncology, it's a question of when, not if. So Clinigen just need to sit on it for a little while and they have a whole brand new explosive market which could completely change this company and put it into the big league. I just hope there's no further silly acquisitions like the recent ones which don't seem to have added much or made sense, just need to keep adding in drugs like Erwinase which are low up front cost and make use of the infrastructure and capacity which has already been invested in.
Iovance can’t seem to agree with the FDA how to measure their therapy for approval purposes.
They have been rejected twice…..it seems per their website.
Whether this is just a delay or whether it becomes an existential issue for their TIL a therapy remains to be proven….the hope is there but delayed…
Anyway the market seems unimpressed.
This will either be a slow recovery or there could be a bid…..but the bid is unlikely to be at what management thought the company was worth a year ago…so my hunch is no bid and a wait of a couple of years to see this back above 800.
For lose interested in IL 2
https://www.drugtargetreview.com/article/71795/the-next-generation-of-cancer-immunotherapies-re-exploring-the-il-2-pathway/